BIOMAT Database Logo BIOMAT Database Logo

[The effects of atrial natriuretic peptide on left ventricular function in subjects with heart failure]. 1991

C Indolfi, and F Piscione, and M Volpe, and G Lembo, and P De Campora, and E Russolillo, and V Ambrosini, and M Condorelli, and M Chiariello
Istituto di Medicina Interna, II Facoltà di Medicina e Chirugia, Università degli Studi Federico II, Napoli.

The effects of atrial natriuretic peptide (ANP) infusion was evaluated in 11 patients with congestive heart failure undergoing cardiac catheterization. Data were obtained at rest and during steady-state phase of alpha-human (1-28) ANP infusion (1 microgram/kg bolus dose, 0.1 microgram/kg/min iv for 30 min). Mean blood pressure decreased from 104 +/- 20 to 89 +/- 21 mmHg (p less than 0.05) 15 min after ANP infusion, as well as left ventricular end-diastolic pressure (from 27 +/- 6 to 14 +/- 11 mmHg, p less than 0.05) and wedge pressure (from 22 +/- 5 to 13 +/- 7 mmHg, p less than 0.05). Left ventricular ejection fraction increased significantly after ANP infusion from 39 +/- 7 to 47 +/- 2%, p less than 0.01. The ANP infusion significantly increased cardiac output from 4.9 +/- 0.8 to 5.8 +/- 1.41/min, p less than 0.05, and decreased the relaxation constant from 69 +/- 17 to 48 +/- 18, p less than 0.05. These results demonstrate that in patients with congestive heart failure ANP infusion decreased wedge pulmonary pressure, left ventricular end-diastolic pressure and increased cardiac output and left ventricular ejection fraction.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009320 Atrial Natriuretic Factor A potent natriuretic and vasodilatory peptide or mixture of different-sized low molecular weight PEPTIDES derived from a common precursor and secreted mainly by the HEART ATRIUM. All these peptides share a sequence of about 20 AMINO ACIDS. ANF,ANP,Atrial Natriuretic Peptide,Atrial Natriuretic Peptides,Atriopeptins,Auriculin,Natriuretic Peptides, Atrial,ANF (1-126),ANF (1-28),ANF (99-126),ANF Precursors,ANP (1-126),ANP (1-28),ANP Prohormone (99-126),ANP-(99-126),Atrial Natriuretic Factor (1-126),Atrial Natriuretic Factor (1-28),Atrial Natriuretic Factor (99-126),Atrial Natriuretic Factor Precursors,Atrial Natriuretic Factor Prohormone,Atrial Natriuretic Peptide (1-126),Atrial Pronatriodilatin,Atriopeptigen,Atriopeptin (1-28),Atriopeptin (99-126),Atriopeptin 126,Atriopeptin Prohormone (1-126),Cardiodilatin (99-126),Cardiodilatin Precursor,Cardionatrin I,Cardionatrin IV,Prepro-ANP,Prepro-CDD-ANF,Prepro-Cardiodilatin-Atrial Natriuretic Factor,Pro-ANF,ProANF,Proatrial Natriuretic Factor,Pronatriodilatin,alpha ANP,alpha-ANP Dimer,alpha-Atrial Natriuretic Peptide,beta-ANP,beta-Atrial Natriuretic Peptide,gamma ANP (99-126),gamma-Atrial Natriuretic Peptide,Natriuretic Peptide, Atrial,Peptide, Atrial Natriuretic,Peptides, Atrial Natriuretic,Prepro ANP,Prepro CDD ANF,Prepro Cardiodilatin Atrial Natriuretic Factor,Pro ANF,alpha ANP Dimer,alpha Atrial Natriuretic Peptide,beta ANP,beta Atrial Natriuretic Peptide,gamma Atrial Natriuretic Peptide
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006328 Cardiac Catheterization Procedures in which placement of CARDIAC CATHETERS is performed for therapeutic or diagnostic procedures. Catheterization, Cardiac,Catheterization, Heart,Heart Catheterization,Cardiac Catheterizations,Catheterizations, Cardiac,Catheterizations, Heart,Heart Catheterizations
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

C Indolfi, and F Piscione, and M Volpe, and G Lembo, and P De Campora, and E Russolillo, and V Ambrosini, and M Condorelli, and M Chiariello
Effects of atrial natriuretic peptide on left ventricular function in hypertension.
September 1994, Hypertension (Dallas, Tex. : 1979),
C Indolfi, and F Piscione, and M Volpe, and G Lembo, and P De Campora, and E Russolillo, and V Ambrosini, and M Condorelli, and M Chiariello
Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: beneficial effects on left ventricular function.
July 1987, Circulation,
C Indolfi, and F Piscione, and M Volpe, and G Lembo, and P De Campora, and E Russolillo, and V Ambrosini, and M Condorelli, and M Chiariello
Atrial natriuretic peptide and left atrial systolic function in normal subjects.
November 1993, Angiology,
C Indolfi, and F Piscione, and M Volpe, and G Lembo, and P De Campora, and E Russolillo, and V Ambrosini, and M Condorelli, and M Chiariello
Effects of atrial natriuretic peptide on left ventricular performance in conscious dogs before and after pacing-induced heart failure.
November 1999, The Journal of pharmacology and experimental therapeutics,
C Indolfi, and F Piscione, and M Volpe, and G Lembo, and P De Campora, and E Russolillo, and V Ambrosini, and M Condorelli, and M Chiariello
Atrial natriuretic peptide as a marker of heart failure in children with left ventricular volume overload.
January 2013, Journal of paediatrics and child health,
C Indolfi, and F Piscione, and M Volpe, and G Lembo, and P De Campora, and E Russolillo, and V Ambrosini, and M Condorelli, and M Chiariello
[Atrial natriuretic factor and brain natriuretic peptide. Variations in elderly subjects with heart failure].
December 1995, Presse medicale (Paris, France : 1983),
C Indolfi, and F Piscione, and M Volpe, and G Lembo, and P De Campora, and E Russolillo, and V Ambrosini, and M Condorelli, and M Chiariello
Correlation of left ventricular ejection fraction and plasma atrial natriuretic peptide in congestive heart failure.
September 1986, The New England journal of medicine,
C Indolfi, and F Piscione, and M Volpe, and G Lembo, and P De Campora, and E Russolillo, and V Ambrosini, and M Condorelli, and M Chiariello
Effects of atrial natriuretic peptide on myocardial contractile and diastolic function in patients with heart failure.
July 1992, Journal of the American College of Cardiology,
C Indolfi, and F Piscione, and M Volpe, and G Lembo, and P De Campora, and E Russolillo, and V Ambrosini, and M Condorelli, and M Chiariello
The effects of left ventricular diastolic function on natriuretic peptide levels after cardioversion of atrial fibrillation.
April 2009, Kardiologia polska,
C Indolfi, and F Piscione, and M Volpe, and G Lembo, and P De Campora, and E Russolillo, and V Ambrosini, and M Condorelli, and M Chiariello
Atrial natriuretic peptide in heart failure.
October 1993, Journal of the American College of Cardiology,
Copied contents to your clipboard!